Tags : HER2-positive Breast Cancer

Seattle Genetics Report Updated Results of Tukysa (tucatinib) in HER2CLIMB

Shots: HER2CLIMB study involves assessing of Tukysa (tucatinib) + trastuzumab + capecitabine vs trastuzumab + capecitabine alone in 612 patients in a ratio (2:1) with LA unresectable/m-HER2+ BC prior treated with trastuzumab, pertuzumab, and T-DM1 Updated results: 42% reduction in the risk of death, 68% reduction in the risk of CNS disease; intracranial response rate […]Read More

Roche Reports Acceptance of BLA for Fixed-Dose SC Combination of

Shots: The BLA is based on P-III FeDeriCa study assessing FDC of Perjeta + Herceptin (SC) + CT vs Perjeta + Herceptin (IV) + CT in 500 patients with HER2-positive eBC who are being treated in the neoadjuvant & adjuvant settings The P-III FeDeriCa study resulted in meeting its 1EPs & 2EPs i.e. non-inferior levels […]Read More

Roche Reports Results of Perjeta (pertuzumab) Fixed Dose SC Combination

Shots: The P-III FeDeriCa study involves assessing of Perjeta (pertuzumab) and Herceptin (trastuzumab) as FDC in SC formulation + CT (IV) vs its standard IV Infusion formulation + CT in patients with HER2-positive eBC, being treated with neoadjuvant and adjuvant setting The P-III FeDeriCa study results: reduction in the time spent for receiving treatment, loading […]Read More